AR083100A1 - Monohidrato de derivados de aza-adamantano - Google Patents

Monohidrato de derivados de aza-adamantano

Info

Publication number
AR083100A1
AR083100A1 ARP110103496A ARP110103496A AR083100A1 AR 083100 A1 AR083100 A1 AR 083100A1 AR P110103496 A ARP110103496 A AR P110103496A AR P110103496 A ARP110103496 A AR P110103496A AR 083100 A1 AR083100 A1 AR 083100A1
Authority
AR
Argentina
Prior art keywords
monohidrate
aza
azatricyclo
thiadiazol
yloxy
Prior art date
Application number
ARP110103496A
Other languages
English (en)
Inventor
Shuang Chen
James J Napier
Geogg G Z Zhang
Paul J Brackemeyer
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44736085&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR083100(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of AR083100A1 publication Critical patent/AR083100A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Forma cristalina monohidrato del citrato diácido de (4s)-4-(5-fenil-1,3,4-tiadiazol-2-iloxi)-1-azatriciclo[3.3.1.13,7]decano, composiciones que comprenden dicho compuesto y un proceso para preparar el compuesto.Reivindicación 1: Una forma cristalina monohidrato del citrato diácido de (4s)-4-(5-fenil-1,3,4-tiadiazol-2-iloxi)-1-azatriciclo[3.3.1.13,7]decano, caracterizada porque el (4s)-4-(5-fenil-1,3,4-tiadiazol-2-iloxi)-1-azatriciclo[3.3.1.13,7]decano está representada por la fórmula (1) y en donde el citrato diácido está representado por la fórmula (2).
ARP110103496A 2010-09-23 2011-09-23 Monohidrato de derivados de aza-adamantano AR083100A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38567410P 2010-09-23 2010-09-23

Publications (1)

Publication Number Publication Date
AR083100A1 true AR083100A1 (es) 2013-01-30

Family

ID=44736085

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110103496A AR083100A1 (es) 2010-09-23 2011-09-23 Monohidrato de derivados de aza-adamantano

Country Status (25)

Country Link
US (2) US9464078B2 (es)
EP (1) EP2619205B1 (es)
JP (2) JP2013537912A (es)
KR (1) KR20130108586A (es)
CN (2) CN103180321A (es)
AR (1) AR083100A1 (es)
AU (1) AU2011305462B2 (es)
BR (2) BR122014023207A2 (es)
CA (1) CA2809675A1 (es)
CL (2) CL2013000756A1 (es)
CO (1) CO6720965A2 (es)
CR (2) CR20130169A (es)
DO (2) DOP2013000064A (es)
EC (1) ECSP13012575A (es)
GT (1) GT201300064A (es)
MX (1) MX2013003344A (es)
NZ (2) NZ609761A (es)
PE (1) PE20131394A1 (es)
PH (1) PH12013500541A1 (es)
RU (2) RU2016105706A (es)
SG (2) SG2014013460A (es)
TW (2) TW201626996A (es)
UA (1) UA110802C2 (es)
UY (1) UY33628A (es)
WO (1) WO2012040404A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
CN103180321A (zh) 2010-09-23 2013-06-26 Abbvie公司 氮杂金刚烷衍生物的一水合物
US8802693B1 (en) 2011-03-09 2014-08-12 Abbvie Inc. Azaadamantane derivatives and methods of use
US20130317055A1 (en) * 2012-05-24 2013-11-28 Abbvie Inc. Neuronal nicotinic agonist and methods of use
US8969562B2 (en) 2013-03-12 2015-03-03 Abbvie, Inc. Azaadamantane formate ester and process for preparing azaadamantane derivatives
AU2014361790B2 (en) * 2013-12-13 2019-05-23 Allergan, Inc. Polymorphic and amorphous forms of cortisol 17-alpha-benzoate and methods for the preparation and use thereof
WO2016100184A1 (en) 2014-12-16 2016-06-23 Forum Pharmaceuticals, Inc. Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
MX2017016231A (es) 2015-06-10 2018-11-29 Axovant Sciences Gmbh Compuestos de aminobencisoxazol como agonistas de receptores a7-nicotínicos de acetilcolina.
WO2017027600A1 (en) 2015-08-12 2017-02-16 Forum Pharmaceuticals, Inc. GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF α7-NICOTINIC ACETYLCHOLINE RECEPTORS

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2514006A1 (fr) 1981-10-05 1983-04-08 Nativelle Sa Ets Acylamino-4 aza-1 adamantanes, procede pour leur preparation, et application en therapeutique
EP0088484A1 (en) 1982-02-04 1983-09-14 Fbc Limited Herbicidal thiadiazolyl N-aminoureas
GB8523211D0 (en) 1985-09-19 1985-10-23 Beecham Group Plc Compounds
EP0350130A3 (en) 1988-07-07 1991-07-10 Duphar International Research B.V New substituted 1,7-annelated 1h-indazoles
US5260303A (en) 1991-03-07 1993-11-09 G. D. Searle & Co. Imidazopyridines as serotonergic 5-HT3 antagonists
US5385912A (en) 1991-03-08 1995-01-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
CA2105655A1 (en) 1991-03-08 1992-09-09 Kent Neuenschwander Multicyclic tertiary amine polyaromatic squalene synthetase inhibitors
US5280028A (en) 1992-06-24 1994-01-18 G. D. Searle & Co. Benzimidazole compounds
US5434151A (en) 1992-08-24 1995-07-18 Cytomed, Inc. Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
US5840903A (en) 1992-07-27 1998-11-24 G. D. Searle & Co. 4-aminomethyl-1-azaadamantane derived benzamides
JP3235913B2 (ja) 1993-07-30 2001-12-04 エーザイ株式会社 アミノ安息香酸誘導体
US5399562A (en) 1994-02-04 1995-03-21 G. D. Searle & Co. Indolones useful as serotonergic agents
US5646289A (en) 1994-10-24 1997-07-08 Eli Lilly And Company Heterocyclic compounds and their preparation and use
US5852037A (en) 1995-11-13 1998-12-22 Eli Lilly And Company Method for treating anxiety
WO1997020819A1 (en) 1995-12-06 1997-06-12 Eli Lilly And Company Composition for treating pain
WO1998027983A1 (en) 1996-12-20 1998-07-02 Novo Nordisk A/S A method of treating hypercholesterolemia and related disorders
US7732163B2 (en) 1997-08-21 2010-06-08 Board Of Trustees Of The University Of Arkansas Extracellular serine protease
US6875606B1 (en) 1997-10-23 2005-04-05 The United States Of America As Represented By The Department Of Veterans Affairs Human α-7 nicotinic receptor promoter
US8236500B2 (en) 1997-10-23 2012-08-07 The United States Of America, As Represented By The Department Of Veterans Affairs Promoter variants of the alpha-7 nicotinic acetylcholine receptor
US6362178B1 (en) 1997-11-12 2002-03-26 Bayer Aktiengesellschaft 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
US6057446A (en) 1998-04-02 2000-05-02 Crooks; Peter Anthony Certain 1-aza-tricyclo [3.3.1-13,7 ] decane compounds
WO1999051602A1 (en) 1998-04-02 1999-10-14 R.J. Reynolds Tobacco Company Azatricyclo[3.3.1.1] decane derivatives and pharmaceutical compositions containing them
US5986100A (en) 1998-04-02 1999-11-16 Crooks; Peter Anthony Pharmaceutical compositions and methods for use
US5952339A (en) 1998-04-02 1999-09-14 Bencherif; Merouane Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release
US6277870B1 (en) 1998-05-04 2001-08-21 Astra Ab Use
EP1083889B1 (en) 1998-06-01 2003-12-10 Ortho-McNeil Pharmaceutical, Inc. Tetrahydronaphtalene compounds and their use for the treatment of neurodegenerative diseases
TR200100462T2 (tr) 1998-08-18 2001-09-21 Ucb, S.A. Muskarinik agonistleri ve antagonistleri
EP1177196B1 (en) 1999-05-04 2004-03-10 Neurosearch A/S Heteroaryl diazabicycloalkanes, their preparation and use
MXPA01012202A (es) 1999-05-24 2002-06-21 Targacept Inc Composiciones farmaceuticas y metodos de uso.
US20010031771A1 (en) 1999-05-24 2001-10-18 Gary Maurice Dull Pharmaceutical compositions and methods for use
EP1233979A1 (en) 1999-12-01 2002-08-28 Ortho-McNeil Pharmaceutical, Inc. Method of diagnosing neurodegenerative disease
AU2001257449A1 (en) 2000-05-01 2001-11-12 Targacept, Inc. Imaging of nicotinic acetylcholine receptor subtypes
ATE287888T1 (de) 2000-07-04 2005-02-15 Neurosearch As Aryl- und heteroaryldiazabicycloalkane, deren zubereitung und verwendung
AUPR213700A0 (en) 2000-12-18 2001-01-25 Biota Scientific Management Pty Ltd Antiviral agents
US7112593B2 (en) 2001-03-27 2006-09-26 Eisai Co., Ltd. N-aryl-substituted cyclic amine derivative and medicine containing the same as active ingredient
US20030124028A1 (en) * 2001-08-10 2003-07-03 Carlson Eric D. Apparatuses and methods for creating and testing pre-formulations and systems for same
FR2832713B1 (fr) 2001-11-23 2004-02-13 Sanofi Synthelabo Derives de 4-(1,3,4-thiadiazol-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
EP1463481A4 (en) 2001-12-14 2008-06-25 Targacept Inc METHOD AND COMPOSITIONS FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM
DE60310548T2 (de) 2002-05-07 2007-05-10 Neurosearch A/S Diazabicyclische biarylderivate
US7049374B2 (en) 2002-07-18 2006-05-23 Chevron U.S.A. Inc. Heterodiamondoids
AU2003250322B2 (en) 2002-08-14 2010-01-21 Neurosearch A/S Novel quinuclidine derivatives and their use
US7030112B2 (en) 2003-03-25 2006-04-18 Bristol-Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
AU2004229237B2 (en) 2003-04-16 2009-06-04 Merck Serono Sa Use of SLURP-1 for treating diseases related to acetylcholine receptors dysfunction
US7202363B2 (en) 2003-07-24 2007-04-10 Abbott Laboratories Thienopyridine and furopyridine kinase inhibitors
EP1663204B1 (en) 2003-08-29 2014-05-07 Exelixis, Inc. C-kit modulators and methods of use
US7399765B2 (en) 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
US20050065178A1 (en) 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
TWI331154B (en) 2003-11-12 2010-10-01 Solvay Pharm Gmbh Novel 17-hydroxysteroid dehydrogenase type i inhibitors
EP1824848A1 (en) 2004-12-10 2007-08-29 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
JP2005232071A (ja) 2004-02-19 2005-09-02 Kanto Chem Co Inc ピラゾール誘導体
JP2007535553A (ja) 2004-04-29 2007-12-06 アボット・ラボラトリーズ アミノ−テトラゾール類縁体および使用方法
CN1964956B (zh) 2004-05-24 2013-03-27 安美基公司 11-β-羟基类固醇脱氢酶1型的抑制剂
PE20060437A1 (es) 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
FR2872165B1 (fr) 2004-06-24 2006-09-22 Sod Conseils Rech Applic Nouveaux derives de pyrimido-benzimidazole
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
ATE553077T1 (de) 2004-07-23 2012-04-15 Nuada Llc Peptidaseinhibitoren
EP1781265B1 (en) 2004-08-25 2010-04-07 Essentialis, Inc. Pharmaceutical formulations of potassium atp channel openers and uses thereof
EP1802616B1 (en) 2004-10-15 2011-01-12 NeuroSearch A/S Novel azabicyclic aryl derivatives and their medical use
EP1805183B1 (en) 2004-10-20 2010-12-29 NeuroSearch A/S Novel diazabicyclic aryl derivatives and their medical use
US9274099B2 (en) 2005-07-22 2016-03-01 The Board Of Trustees Of The Leland Stanford Junior University Screening test drugs to identify their effects on cell membrane voltage-gated ion channel
EP1919497B1 (en) 2005-07-22 2020-02-12 The Board of Trustees of the Leland Stanford Junior University Light-activated cation channel and uses thereof
US7897766B2 (en) 2005-09-23 2011-03-01 Abbott Laboratories Amino-aza-adamantane derivatives and methods of use
CA2632642A1 (en) 2005-12-06 2007-06-14 Neurosearch A/S Novel diazabicyclic aryl derivatives and their medical use
US20090291976A1 (en) 2006-06-27 2009-11-26 Peter Andrew Ferchmin Neuronal circuit-dependent neuroprotection by interaction between nicotinic receptors
FR2905009A1 (fr) 2006-08-18 2008-02-22 Servier Lab Methode de criblage de composes aux proprietes anti-amyloide
US20100234349A1 (en) 2006-09-04 2010-09-16 Olsen Gunnar M Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
AU2007309390A1 (en) 2006-10-27 2008-05-02 Medivation Neurology, Inc. Methods and combination therapies for treating Alzheimer's disease
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
CN101541792A (zh) * 2006-11-06 2009-09-23 艾博特公司 氮杂金刚烷衍生物和应用方法
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
KR20090107567A (ko) 2007-02-09 2009-10-13 아스텔라스세이야쿠 가부시키가이샤 아자 가교환 화합물
WO2008106694A2 (en) 2007-03-01 2008-09-04 The Board Of Trustees Of The Leland Stanford Junior University Systems, methods and compositions for optical stimulation of target cells
WO2008112177A2 (en) 2007-03-08 2008-09-18 Genizon Biosciences, Inc. Genemap of the human genes associated with schizophrenia
ATE509931T1 (de) 2007-03-23 2011-06-15 Abbott Lab Azaadamantanester- und carbamatderivate sowie anwendungsverfahren dafür
EP2322168A1 (en) 2007-04-02 2011-05-18 Parkinson's Institute Methods and Compositions for Reduction of Side Effects of Therapeutic Treatments
WO2009017454A1 (en) 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
US8697722B2 (en) 2007-11-02 2014-04-15 Sri International Nicotinic acetylcholine receptor modulators
WO2009058120A1 (en) 2007-11-02 2009-05-07 Sri International Nicotinic acetylcholine receptor modulators
JP5436222B2 (ja) 2007-11-20 2014-03-05 日産化学工業株式会社 ２−アザアダマンタン類の製造方法
DE102007058504A1 (de) 2007-12-05 2009-07-09 Acino Ag Transdermales therapeutisches System mit einem Gehalt an einem Modulator für nikotinische Acetylcholinrezeptoren (nAChR)
JP2011511845A (ja) 2008-02-13 2011-04-14 ターガセプト，インコーポレイテッド アルファ７（α７）ニコチン作動薬と抗精神病薬との組合せ物
US20090239901A1 (en) 2008-03-19 2009-09-24 Merouane Bencherif Method and compositions for treatment of cerebral malaria
US20110098312A1 (en) 2008-05-12 2011-04-28 Targacept ,Inc Methods for preventing the development of retinopathy by the oral administration of nnr ligands
FR2931677B1 (fr) 2008-06-02 2010-08-20 Sanofi Aventis Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
US20110097324A1 (en) 2008-06-13 2011-04-28 Centre For Addiction And Mental Health Compositions and methods for modulating nicotinic/nmda receptor function
US8841329B2 (en) 2008-09-11 2014-09-23 Dignity Health Nicotinic attenuation of CNS inflammation and autoimmunity
EP2344636B1 (en) 2008-10-09 2017-12-06 Howard Hughes Medical Institute Novel chimeric ligand-gated ion channels and methods of use thereof
US20110262407A1 (en) 2008-11-11 2011-10-27 Targacept, Inc. Treatment with alpha7 selective ligands
WO2010088400A1 (en) 2009-01-28 2010-08-05 Catholic Healthcare West Methods of diagnosing and treating neurodegenerative diseases
RU2012107101A (ru) 2009-07-31 2013-09-10 Байокрист Фармасьютикалз, Инк. Производные пирроло[1,2-в] пиридазина как ингибиторы янус-киназы
JP2013502427A (ja) 2009-08-21 2013-01-24 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド アナバセイン化合物の制御放出製剤およびその使用
US20120270844A1 (en) 2009-10-09 2012-10-25 Afraxis, Inc. Methods for treating alzheimer's disease
WO2011058582A1 (en) 2009-11-16 2011-05-19 Orchid Research Laboratories Ltd. Histone deacetylase inhibitors for the treatment of fungal infections
CN103180321A (zh) 2010-09-23 2013-06-26 Abbvie公司 氮杂金刚烷衍生物的一水合物
EP2441755A1 (en) 2010-09-30 2012-04-18 Almirall, S.A. Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors
WO2012059932A1 (en) 2010-11-01 2012-05-10 Aurigene Discovery Technologies Limited 2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors

Also Published As

Publication number Publication date
UA110802C2 (uk) 2016-02-25
DOP2013000249A (es) 2014-01-15
CL2013000756A1 (es) 2013-07-12
WO2012040404A1 (en) 2012-03-29
CN103180321A (zh) 2013-06-26
BR122014023207A2 (pt) 2019-05-28
TW201212914A (en) 2012-04-01
JP2017039764A (ja) 2017-02-23
EP2619205B1 (en) 2017-05-17
CA2809675A1 (en) 2012-03-29
RU2579121C2 (ru) 2016-03-27
DOP2013000064A (es) 2013-07-15
UY33628A (es) 2012-03-30
RU2016105706A (ru) 2018-11-22
KR20130108586A (ko) 2013-10-04
CR20130594A (es) 2014-01-31
EP2619205A1 (en) 2013-07-31
PH12013500541A1 (en) 2013-05-06
CR20130169A (es) 2013-06-12
SG188307A1 (en) 2013-04-30
CO6720965A2 (es) 2013-07-31
AU2011305462A1 (en) 2013-03-21
BR112013005434A2 (pt) 2016-06-07
RU2013118560A (ru) 2014-10-27
SG2014013460A (en) 2014-09-26
NZ609761A (en) 2015-10-30
AU2011305462B2 (en) 2015-11-26
MX2013003344A (es) 2013-06-28
US9464078B2 (en) 2016-10-11
ECSP13012575A (es) 2013-07-31
US20120245195A1 (en) 2012-09-27
TW201626996A (zh) 2016-08-01
PE20131394A1 (es) 2014-01-11
CL2014000651A1 (es) 2014-09-05
NZ707955A (en) 2016-03-31
GT201300064A (es) 2014-07-11
CN106074548A (zh) 2016-11-09
JP2013537912A (ja) 2013-10-07
US20150239882A1 (en) 2015-08-27

Similar Documents

Publication Publication Date Title
AR083100A1 (es) Monohidrato de derivados de aza-adamantano
CR20120277A (es) Una forma cristalina y amorfa de genz 112638 hemitartrato como inhibidores de glucosilceramida sintasa
MX378354B (es) Mejoramiento de autofagia o incremento de longevidad por administracion de urolitinas o precursores de las mismas.
IN2014MN02106A (es)
MX2011008176A (es) Derivados de 3,3&#39;-espiroindolinona como agentes anticancerigenos.
MX2010012298A (es) Activadores de glucocinasa.
PE20120989A1 (es) Sales de disacarina, acido difumarico, acido d-1-hidroxi-2-naftoico y monobenzoico del 2-(4-((2-amino-4-metil-6-(pentilamino) pirimidin-5-il) metil) fenil) acetato de 4-(dimetilamino) butilo
MX2015010354A (es) Derivados de acido betulinico modificados con aquilo c-3 y alquenilo utiles en el tratamiento de virus de inmunodeficiencia humana (vih).
MY160785A (en) Manufacturing process for pyrimidine derivatives
CR20110403A (es) Derivados de tiadiazoles y oxadiazoles, su preparación y su aplicación en terapia
EP3404032A3 (en) Process for making benzoxazepin compounds
CL2011000296A1 (es) Proceso de preparación del ester metílico del ácido 4-oxo-octahidro-indol-1-carboxílico y compuestos intermediarios utilizados.
CR20160016A (es) Pirazolpiridinas sustituidas
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
AR076709A1 (es) Piperidinas sustituidas como antagonistas de par-1 y un procedimiento para su preparacion
UA106886C2 (uk) Спосіб одержання 1-бензил-3-гідроксиметил-1h-індазолу і його похідних та проміжні сполуки магнію
CL2011003123A1 (es) Compuestos derivados de ciclopentanamida sustituidos; composicion farmaceutica; proceso de obtencion; y uso en el tratamiento o la profilaxis de la diabetes, aterosclerosis, entre otras.
MX2013000294A (es) Intermedios y procedimiento de preparación de un inhibidor específico de la trombina.
MX2011011716A (es) Derivados de isoquinolina novedosos.
MX2013002694A (es) Derivados de tetrahidroquinolina usados como activadores de proteina cinasa activada por monofosfato de adenosina.
NI200900154A (es) Nuevos procedimiento de obtención de la forma cristalina v de la agomelatina
CL2012001081A1 (es) Procesos de preparcion de compuestos intermediarios en la sintesis de valsartan por hidrolisis de un ester utilizando salesde aluminio.
GEP20125545B (en) New chromene compounds, a process for their preparation and pharmaceutical compositions containing them
TW201612188A (en) The L-proline complex, monohydrate and crystal of a sodium-glucose contransporter 2 inhibitor
ECSP11011150A (es) Derivados de arilciclopropilacetamida útiles como activadores de glucoquinasa

Legal Events

Date Code Title Description
FB Suspension of granting procedure